Did Strong New Signatera ctDNA Data Just Shift Natera’s (NTRA) Investment Narrative?

Simply Wall St.12-20 17:10

Natera recently reported that the phase III CALGB (Alliance)/SWOG 80702 trial, now published in JAMA Oncology, showed that adding celecoxib to FOLFOX chemotherapy after surgery reduced recurrence and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592143365?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-20 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592143365","market":"sg","top_or_hot":-1,"title":"Did Strong New Signatera ctDNA Data Just Shift Natera’s (NTRA) Investment Narrative?","media":"Simply Wall St.","content":"<div>\n<p>Natera recently reported that the phase III CALGB (Alliance)/SWOG 80702 trial, now published in JAMA Oncology, showed that adding celecoxib to FOLFOX chemotherapy after surgery reduced recurrence and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/did-strong-new-signatera-ctdna-data-just-shift-nateras-ntra\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Did Strong New Signatera ctDNA Data Just Shift Natera’s (NTRA) Investment Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDid Strong New Signatera ctDNA Data Just Shift Natera’s (NTRA) Investment Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-20 17:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/did-strong-new-signatera-ctdna-data-just-shift-nateras-ntra><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Natera recently reported that the phase III CALGB (Alliance)/SWOG 80702 trial, now published in JAMA Oncology, showed that adding celecoxib to FOLFOX chemotherapy after surgery reduced recurrence and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/did-strong-new-signatera-ctdna-data-just-shift-nateras-ntra\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1064131342.USD","symbol_name":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/did-strong-new-signatera-ctdna-data-just-shift-nateras-ntra","article_id":"2592143365","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/did-strong-new-signatera-ctdna-data-just-shift-nateras-ntra","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592143365","pubTimestamp":1766221827,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Natera recently reported that the phase III CALGB (Alliance)/SWOG 80702 trial, now published in JAMA Oncology, showed that adding celecoxib to FOLFOX chemotherapy after surgery reduced recurrence and death risk in Signatera-positive stage III colorectal cancer patients, while multiple new breast cancer studies further reinforced the prognostic power of its Signatera ctDNA assays.\nTogether with a fresh MiRaDoR collaboration in hormone receptor-positive breast cancer and updated PALLAS MRD...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4139":"生物科技","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","NTRA":"Natera, Inc.","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC"},"translate_title":"强劲的新Signatera ctDNA数据是否改变了Natera(NTRA)的投资叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1.5},"content_text":"Natera recently reported that the phase III CALGB (Alliance)/SWOG 80702 trial, now published in JAMA Oncology, showed that adding celecoxib to FOLFOX chemotherapy after surgery reduced recurrence and death risk in Signatera-positive stage III colorectal cancer patients, while multiple new breast cancer studies further reinforced the prognostic power of its Signatera ctDNA assays. Together with a fresh MiRaDoR collaboration in hormone receptor-positive breast cancer and updated PALLAS MRD data, these results deepen Signatera’s role in guiding adjuvant treatment choices and refining recurrence risk across several major tumor types. We’ll now explore how this strengthened evidence that Signatera can identify patients benefiting from celecoxib may influence Natera’s investment narrative. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 34 best rare earth metal stocks of the very few that mine this essential strategic resource.Natera Investment Narrative RecapTo own Natera, you need to believe that molecular residual disease testing like Signatera will become embedded in standard oncology care, supporting sustained revenue growth despite current losses and high R&D spend. The new CALGB/SWOG 80702 data strengthen Signatera’s clinical relevance, but they do not remove the near term profitability risk from heavy investment and potential reimbursement or regulatory shifts. Among recent updates, the PALLAS MRD results in HR+/HER2 negative breast cancer are especially relevant, as they echo the colorectal data by showing Signatera’s ability to stratify recurrence risk across large, late stage trials. Together, these datasets feed the key catalyst of broader clinical adoption and payer support for Signatera guided care, even as Natera continues to run at a loss and invests heavily in new studies. However, despite growing validation, investors should be aware that tighter reimbursement policies or delays in new coverage decisions could... Read the full narrative on Natera (it's free!)Natera's narrative projects $3.0 billion revenue and $110.9 million earnings by 2028.Uncover how Natera's forecasts yield a $234.68 fair value, in line with its current price.Exploring Other PerspectivesNTRA 1-Year Stock Price Chart Eight fair value estimates from the Simply Wall St Community range widely from US$65.39 to US$268, reflecting very different expectations. You can set those views against the central catalyst of growing clinical adoption and reimbursement for Signatera, which could have a meaningful impact on how Natera’s future performance is judged.Explore 8 other fair value estimates on Natera - why the stock might be worth as much as 16% more than the current price!Build Your Own Natera NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Natera research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Every day counts. These free picks are already gaining attention. See them before the crowd does:Find companies with promising cash flow potential yet trading below their fair value.These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.Uncover the next big thing with financially sound penny stocks that balance risk and reward.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentValuation is complex, but we're here to simplify it.Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592143365","isCrawlerRequest":true}